1.646.889.1200|info@lifescipublicrelations.com

Twice as Splice

//Twice as Splice

Twice as Splice

Abivax S.A. (Euronext:ABVX) has positioned its anti-HIV therapy ABX464 to take on inflammatory diseases after discovering the small molecule triggers RNA splicing that both halts HIV viral replication and boosts anti-inflammatory responses in HIV and ulcerative colitis. According to CEO Hartmut Ehrlich, ABX464 binds the human cap binding complex (CBC) and promotes its splicing activity.

By | 2018-09-28T10:22:23-04:00 September 27th, 2018|News|Comments Off on Twice as Splice

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.